Literature DB >> 2899060

Geographic distribution of HTLV-I and identification of a new high-risk population.

P H Levine1, W A Blattner, J Clark, R Tarone, E M Maloney, E M Murphy, R C Gallo, M Robert-Guroff, W C Saxinger.   

Abstract

Epidemiologic studies indicate that human T-cell lymphotropic virus type I (HTLV-I), the causative agent of most cases of adult T-cell leukemia/lymphoma (ATLL) in Southeast Japan and the Caribbean islands and the probable cause of a progressive neurological disorder often referred to as tropical spastic paraparesis, occurs with unusual geographic clustering. The current large-scale serosurvey was undertaken to improve our understanding of HTLV-I prevalence in different parts of the world. We analyzed 43,445 serum samples collected from various geographic locales worldwide; 76% of these sera came from clinically healthy donors. Samples were initially screened by an enzyme-linked immunosorbent assay (ELISA) and 4,353 were further evaluated by means of competition assays. In this study, which did not include sera from endemic areas of Japan, a high prevalence of infection was observed in several countries in the Caribbean basin. A significant age-sex difference was observed between populations in the Caribbean and non-endemic regions of Japan. The reason for the male excess in non-endemic areas of Japan will require further study, while the female excess in the Caribbean basin is compatible with the previously described pattern for other HTLV-I-endemic areas. A newly recognized area of possible endemicity was southern Florida, where evidence of infection with HTLV-I or a related virus was found in a group of native Americans whose sera were collected in 1968. In certain parts of the world, particularly sub-Saharan Africa, important problems in determining specificity of reactivity occurred, probably because of cross-reacting antibodies. No pattern was detected that could explain the cross-reactivity solely on the basis of geographic areas, specific patterns of non-viral parasitic infection, or methods of handling the specimens. It is possible that these cross-reactivities are antibodies to proteins from HTLV-I-related retroviruses yet to be discovered.

Entities:  

Mesh:

Year:  1988        PMID: 2899060     DOI: 10.1002/ijc.2910420103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

Review 2.  HTLV-I infection in Britain.

Authors:  J Weber
Journal:  BMJ       Date:  1990-07-14

3.  HTLV-I infection in French West Indies: a case-control study.

Authors:  N Frery; M Chavance; I Valette; L Schaffar; C Neisson-Vernant; J Jouannelle; N Monplaisir
Journal:  Eur J Epidemiol       Date:  1991-03       Impact factor: 8.082

Review 4.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

5.  A serosurvey for HTLV-I among high-risk populations and normal adults in Egypt.

Authors:  N T Constantine; M Fathi Sheba; A L Corwin; R S Danahy; J D Callahan; D M Watts
Journal:  Epidemiol Infect       Date:  1991-10       Impact factor: 2.451

6.  HTLV-1 associated T cell lymphoma in South East Asia: case report and family study.

Authors:  T L Wang; T C Liu; L Chan; Y K Kueh; S Y Wong
Journal:  J Clin Pathol       Date:  1991-08       Impact factor: 3.411

7.  Immunodetection of human T-cell lymphotropic virus type I core protein in biological samples by using a monoclonal antibody immunoassay.

Authors:  L Papsidero; F Swartzwelder; M Sheu; R Montagna; G Ehrlich; S Bhagavati; H Dosik; J Sninsky; B Poiesz
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

8.  Inhibition of HTLV-I induction and virus-induced syncytia formation by oligodeoxynucleotides.

Authors:  N Miyano-Kurosaki; Y Koyanagi; M Mizuguchi; S Ohki; K Makino; N Yamamoto
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

9.  Seroepidemiological survey of HTLV-I infection in French Polynesia, Cook Islands and Fiji.

Authors:  E Chungue; J P Boutin; L Le Marchand; G Philippon; A Le Guellec; S Chanteau; J L Cartel; C Gras; P M Martin; J F Roux
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

10.  Prevalence of HTLV types I and II among drug users in King County, Washington.

Authors:  H Thiede; N V Harris; J P McGough; B Roberts; R F Khabbaz; J E Kaplan
Journal:  West J Med       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.